Li Kewei, Jiang Zheng
Department of Gastroenterology, First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015 Jan;31(1):18-22.
To construct lentiviral vector that interferes with Nanog, investigate its expression in human gastric cancer cell SGC-7901-transplanted nude mice, and explore the effect of shRNA-Nanog transfection on the growth of the xenograft in mice.
Lentivirus carrying shRNA-Nanog was prepared by incorporating previously validated siRNA into Nanog gene specific lentiviral vectors. The models of human gastric cancer transplantation were constructed in nude mice. The mouse models were randomly divided into lentivirus-shRNA-Nanog transfection group (experimental group), GFP infection group (empty vector group) and uninfected group (control group). The tumor volume and mass changes were measured. Small animal in vivo imaging was employed to examine the fluorescent intensity and tumor metastasis. The Nanog protein expression was determined by Western blot analysis. The apoptosis of transinfected tumor cells was analyzed by TUNEL method. Results The gene sequencing demonstrated that the recombinant lentivirus carrying shRNA-Nanog was successfully established. In vivo imaging showed that 27 days after transfection, the total fluorescent intensity in the experimental group was significantly lower than that in the empty vector group or the uninfected group. The xenograft volume and mass in the experimental group decreased significantly as compared with those in the empty vector group or the uninfected group. Western blotting indicated that the expression of Nanog protein in the experimental group was significantly lower than that in the empty vector or uninfected group. TUNEL results revealed that the apoptosis rate in the experimental group was significantly higher than that in the other two groups. No statistically significant difference was found between the empty vector group and the uninfected group.
We successfully established Nanog gene-shRNA expression vector and capsulated it as lentivirus particles, which could inhibit the growth of xenograft in nude mice.
构建干扰Nanog的慢病毒载体,研究其在人胃癌细胞SGC-7901移植裸鼠中的表达,并探讨shRNA-Nanog转染对小鼠移植瘤生长的影响。
将先前验证的siRNA整合到Nanog基因特异性慢病毒载体中,制备携带shRNA-Nanog的慢病毒。在裸鼠中构建人胃癌移植模型。将小鼠模型随机分为慢病毒-shRNA-Nanog转染组(实验组)、GFP感染组(空载体组)和未感染组(对照组)。测量肿瘤体积和质量变化。采用小动物活体成像技术检测荧光强度和肿瘤转移情况。通过蛋白质免疫印迹分析测定Nanog蛋白表达。采用TUNEL法分析转染肿瘤细胞的凋亡情况。结果基因测序表明成功构建了携带shRNA-Nanog的重组慢病毒。活体成像显示,转染27天后,实验组的总荧光强度明显低于空载体组或未感染组。与空载体组或未感染组相比,实验组的移植瘤体积和质量明显减小。蛋白质免疫印迹表明,实验组中Nanog蛋白的表达明显低于空载体组或未感染组。TUNEL结果显示,实验组的凋亡率明显高于其他两组。空载体组和未感染组之间未发现统计学上的显著差异。
成功构建了Nanog基因-shRNA表达载体并将其包装成慢病毒颗粒,其可抑制裸鼠移植瘤的生长。